Read More Pharma Industry News Johnson & Johnson fortifies urologic oncology pipeline with compelling Inlexzo results Johnson & Johnson's new data show Inlexzo delivers strong one-year disease-free survival. Find out how it could shift bladder cancer care. byPallavi MadhirajuDecember 6, 2025